ÂÜÀòÂÒÂ×

Joseph Bolen currently serves as Chief Science Innovation Officer at Orna Therapeutics and a Partner at MPM BioImpact, both positions held since 2024. Bolen has been a Member of the R&D Subcommittee Board of Directors and Chief Scientific Officer at PureTech Health since November 2015. Previous roles include Chief Science Innovation Officer at ReNAgade Therapeutics for a brief period in 2024, and serving on the Board of Directors at Aelin Therapeutics from July 2021 to June 2023. Bolen also held significant positions at Moderna as President R&D/Chief Scientific Officer from May 2013 to September 2015, at Takeda as Global Head Oncology Research from January 2010 to May 2013, and at MILLENNIUM PHARMACEUTICALS, INC. as Chief Scientific Officer and Head of Oncology Research, where tenure spanned from January 1998 to May 2013. Bolen began a distinguished career as Founding Director of the Department of Signal Transduction at DNAX Research Institute of Molecular & Cellular Biology Inc from January 1995 to December 1998.